Related Experiment Video
Updated: Apr 21, 2026
05:30
Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
Published on: August 8, 2025
785
Beta-blockers for hemangiomas
1Unit of Pediatric Dermatology, Department of Surgical and Transplant Pathophysiology Milano University, Fondazione Ca' Granda "Ospedale Maggiore Policlinico",Milan, Italy - ric.cavalli@tiscali.it.
Summary
Infantile hemangiomas (IHs), common infant tumors, often require treatment despite natural regression. Oral propranolol is now the preferred therapy due to its high efficacy and safety profile.
Area of Science:
- Pediatric Oncology
- Dermatology
- Pharmacology
Background:
- Infantile hemangiomas (IHs) are the most common tumors in infancy.
- IHs typically exhibit rapid growth followed by spontaneous involution.
- Treatment is indicated for IHs with rapid growth, critical locations, complications, or functional impairment.
Purpose of the Study:
- To review the current therapeutic landscape for infantile hemangiomas.
- To highlight the role of propranolol in IH management.
- To discuss the efficacy and safety of propranolol for IHs.
Main Methods:
- Literature review of infantile hemangioma treatment modalities.
- Analysis of studies on propranolol's effectiveness in IHs.
- Comparison of propranolol with historical therapies for IHs.
Main Results:
- Oral propranolol has become the first-line systemic treatment for IHs since 2008.
- Propranolol demonstrates nearly 100% efficacy with rapid action and minimal side effects.
- It has replaced older, riskier treatments like oral steroids and vincristine.
Conclusions:
- Oral propranolol has revolutionized infantile hemangioma treatment.
- Its high efficacy and favorable safety profile make it the preferred therapy.
- Formal approvals by FDA and EMA validate its use in IH management.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.7K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
01:28Antihypertensive Drugs: Types of β-Blockers
1.9K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
01:22Heart Failure Drugs: β-Blockers
2.3K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.3K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
01:16Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K